TMCnet News
Gala Global to Begin Sales and Distribution of Its Plant Cloning Incubators to Colorado MarketLAS VEGAS, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTC:GLAG), a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotech industry, today announced that its majority-owned subsidiary, Controlled Environment Genomics Inc., a start-up biotechnology company focused on the development and commercialization of computer controlled digital plant cloning incubators for use in the agricultural and biopharmaceutical industries, has signed a Distributor Agreement with KGBI Colorado to sell the Company’s patent pending fully automated, computer controlled plant cloning incubators initially to Colorado’s large and growing cannabis market. The Company has also completed the first commercial scale production version of its fully automated computer controlled plant cloning Incubators. An initial manufacturing run of the first 100 units is scheduled to begin in December 2017.
A photo accompanying this announcement is available at //www.globenewswire.com/NewsRoom/AttachmentNg/0d10117a-a1da-4c9e-b3fa-1df7778ba4a5 “We are excited to enter into this new business venture with KGBI, representing the second major milestone in the development of our turn-key digital plant cloning incubation systems,” said Gala Global CEO Timothy Madden. “The next major accomplishment will be the completion of the manufacturing run of our first 100 units, with initial revenues expected to begin in January 2018. Based on our existing sales pipeline and our success in developing new innovations in cloning and plant breeding, we believe Gala Global is on the right track to be able to generate substantiall greater revenues and earnings in the weeks and months ahead,” concluded Mr. Madden. Gala Global Inc. subsidiary CEG Inc. is also collaborating with technology partner GenoBreeding Inc., on developing breeding tools such as molecular markers to enable productive plant breeding decisions and processes that achieve top-tier plant performance in a sustainable manner. CEG’s state-of-the-art genomics technology enables GenoBreeding to digitally sequence the genomes of the most desirable plant varieties based on flavor and nutrition, so the desirable traits can be used to improve the most desirable commercial varieties with traits such as increased yield and quality, thus enhancing consumer demand for the product. GenoBreeding is also developing a proprietary digital genetic database that will be used as an online cloud based library of digitally sequenced genomes and phenotypic (chemical composition) information on all existing and new plant varieties. CEG Inc. proprietary digital plant cloning technology will enable GenoBreeding’s geneticists to select the best plant varieties to hybridize, improving and increasing crop quality and yields by combining the very best genetics, maximizing the variation of positive inherited characteristics in each variety. About CEG Inc. About GenoBreeding Inc. About Gala Global Inc. Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Investor/Media Contact: At the Company: |
||||||||